Home / PDA Letter / Full Article

Five Critical Endotoxin Testing Concerns

by Jennifer Farrington, PhD, Associates of Cape Cod, and Friedrich von Wintzingerode, PhD, Roche Diagnostics GmbH

Published On Jul 9, 2018

As pharmaceutical manufacturing processes continue to become more streamlined and therapy delivery continues to evolve, so has endotoxin control. Five topics in particular have dominated recent discussions around endotoxin control: low endotoxin recovery, non-LAL detection methods, modulating impurities, data integrity and depyrogenation.

The contents of "Five Critical Endotoxin Testing Concerns" are available to PDA members. Please sign up or log in to read the full article.